摘要
目的 观察吗替麦考酚酯（MMF）治疗重症肌无力（MG）患者的临床疗效和不良反应.方法 将58例MG住院患者随机分为对照组及治疗组,对照组30例予以口服泼尼松治疗,治疗组28例给予吗替麦考酚酯分散片口服.采用肌无力疲劳程度评分（MWSS）和MG日常生活状况量表（MG-ADL）,比较两组患者治疗前与治疗后1、3、6个月的评分,并观察两组患者的不良反应.结果 两组患者治疗前与治疗后MWSS评分在3个时间段比较差异均无统计学意义（P＞0.05）.治疗后1个月两组MG-ADL评分比较差异有统计学意义（P＜0.05）,治疗后3、6个月两组MG-ADL评分比较差异无统计学意义（P＞0.05）.对照组部分患者出现糖皮质激素常见不良反应.治疗组未见不良反应.结论 单独使用吗替麦考酚酯治疗重症肌无力,在起效时间及治疗有效性方面与使用泼尼松效果相当,且安全性好,可有效避免糖皮质激素激素不良反应.
Objective To observe the clinical effect and adverse reaction of mycophenolate mofetil in patients of myasthenia gravis.Methods 58 cases of hospitalized patients were randomly divided into control group and treatment group,30 cases in control group were given oral prednisone treatment,and 28 cases in treatment group were given oral MMF.Using muscle weakness fatigue rating scale （MWSS）and MG Activities of Daily Living Score（MG-ADL）,to observe the clinical effect and compare scores of the two groups before treatment with after 1 month,3 months and 6 months treatment,then to observe the safety index and adverse reactions.Results On MWSS scoring,comparison between the two groups were not statistical significance at three time points after treatment（P ＞ 0.05）.On MG-ADL scores,it had statistically significant after 1 month treatment between groups（P ＜ 0.05）,but had no statistical significance after 3 and 6 months treatment （P ＞ 0.05）.On safety evaluation,a small number of patients in the control group were found common adverse reactions to glucocorticoid.No adverse reaction in treatment group.Conclusion Patients with MG received single treatment of MMF,could get similar clinical curative effect on the working time and therapeutic effectiveness comparing with treatment of prednisone.It had good safety,which can effectively avoid the adverse reactions of glucocorticoid.
出处
《临床内科杂志》
CAS
2014年第6期407-409,共3页
Journal of Clinical Internal Medicine
关键词
重症肌无力
吗替麦考酚酯
临床疗效
不良反应
Myasthenia Gravis
Mycophenolate mofetil
Clinical efficacy
Adverse reactions
